Data / Form D filings / Character Biosciences, Inc.
Character Biosciences, Inc.: Form D filings
Character Biosciences, Inc., a biotechnology company in Jersey City, NJ, filed 2 Form D notices with the SEC in 2025. The latest, on September 17, 2025, reports $8.9 million sold of a $19.6 million offering to 4 investors.
SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.
Company details from the filing
- Address
- 3 2nd Street, Suite 302, Jersey City, NJ, 07311
- Phone
- (929) 310-5933
- Industry
- Biotechnology
- Entity type
- Corporation
- Incorporated in
- Delaware
- Revenue range
- Decline to Disclose
- Exemptions claimed
- Rule 506(b)
- SEC identifier (CIK)
- 2066192
Form D filings
| Filed | Type | Offering | Sold | Remaining | Investors | First sale | Filing |
|---|---|---|---|---|---|---|---|
| Sep 17, 2025 | New notice | $19,649,993 | $8,855,499 | $10,794,494 | 4 | Sep 2, 2025 | sec.gov |
| May 12, 2025 | New notice | $110,500,000 | $48,174,992 | $62,325,008 | 16 | Mar 20, 2025 | sec.gov |
Executive officers and directors named in the filing
| Name | Role | Note in the filing |
|---|---|---|
| Reut Shema | Director | |
| Vivek Garipalli | Director | |
| Mayssa Attar | Director | |
| James Kasuboski | Director | |
| Cheng Zhang | Executive Officer, Director | |
| Peter DiLaura | Director | |
| Jason Hafler | Director | |
| Nick Olsen | Director |
Other biotechnology companies in New Jersey that filed recently
- Ensho Therapeutics, Inc. $7.3 million · Oct 15, 2026
- Xenon Ophthalmics Inc $3.3 million · Oct 6, 2026
- LISATA THERAPEUTICS, INC. $351.9 million · Oct 2, 2026
- Bullseye Biodevices, Inc. $1.3 million · Aug 10, 2026
- Hepion Pharmaceuticals, Inc. $3.1 million · Aug 5, 2026
Every Form D from the week of Sep 15, 2025 · All recent filings in New Jersey · All recent Biotechnology filings
Read from SEC EDGAR. Amount sold is what Character Biosciences, Inc. reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.